ORKA-004 + ORKA-002

ORKA-004 + ORKA-002 is an investigational combination therapy being developed by Oruka Therapeutics for the treatment of chronic inflammatory skin diseases, such as plaque psoriasis and hidradenitis suppurativa, as well as inflammatory bowel disease (IBD). The combination consists of ORKA-004, a subcutaneously administered, half-life-extended monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A), and ORKA-002, a subcutaneously administered, half-life-extended monoclonal antibody targeting interleukin-17A and interleukin-17F (IL-17A/F). Both components are designed to offer extended dosing intervals (potentially twice yearly or quarterly) compared to existing therapies. Oruka Therapeutics plans to initiate Phase 2 combination studies of ORKA-004 with ORKA-002 in 2027.